Caldera Therapeutics
PrivateLast Round
Series A
Extension
Jan 14, 2026
Total Funding Raised
$112.5M
Company Overview
Caldera Therapeutics is a clinical stage biotechnology company developing CLD-423, a first-in-class bispecific antibody for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Caldera Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Caldera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Jan 14, 2026 | ||||
| Series A | Apr 23, 2025 |
Caldera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series A Extension |
| Omega Funds | Series A Extension |
| Accomplice | Series A Extension, Series A |
| venBio | Series A Extension, Series A |
| Wellington Management | Series A Extension |
Caldera Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Caldera Therapeutics's valuation, stock price, and market status.
